GuaLou GuiZhi decoction inhibits LPS-induced microglial cell motility through the MAPK signaling pathway.

Microglial activation plays an important role in neroinflammation following ischemic stroke. Activated microglial cells can then migrate to the site of injury to proliferate and release substances which induce secondary brain damage. It has been shown that microglial migration is associated with the activation of the mitogen-activated protein kinase (MAPK) signaling pathways. The Chinese formula, GuaLou GuiZhi decoction (GLGZD), has long been administered in clinical practice for the treatment of post-stroke disabilities, such as muscular spasticity. In a previous study, we demonstrated that the anti-inflammtory effects of GLGZD were mediated by the TLR4/NF-κB pathway in lipopolysaccharide (LPS)-stimulated microglial cells. Therefore, in this study, we evaluated the role of GLGZD in microglial migration by performing scratch wound assays and migration assays. We wished to elucidate the cellular and molecular mechanisms elicited by this TCM formula in microglial-induced inflammation by evaluating the release and expression of chemotactic cytokines [monocyte chemo-attractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and interleukin (IL)-8] by ELISA and quantitative PCR. Our results revealed that the migration of microglial cells was enhanced in the presence of LPS (100 ng/ml); however, GLGZD (100 µg/ml) significantly inhibited cell motility and the production of chemokines through the inhibition of the activation of the p38 and c-Jun N-terminal protein kinase (JNK) signaling pathway. We demonstrate the potential of GLGZD in the modulation of microglial motility by investigating the effects of GLGZD on microglial migration induced by LPS. Taken together, our data suggest that GLGZD per se cannot trigger microglial motility, whereas GLGZD impedes LPS-induced microglial migration through the activation of the MAPK signaling pathway. These results provide further evidence of the anti-inflammatory effects of GLGZD and its potential for use in the treatment of ischemic stroke.

[1]  J. Mclarnon,et al.  Microglial chemotactic signaling factors in Alzheimer's disease. , 2012, American journal of neurodegenerative disease.

[2]  S. Rivest.  Molecular insights on the cerebral innate immune system , 2003, Brain, Behavior, and Immunity.

[3]  E. H. Lee,et al.  5-Chloroacetyl-2-amino-1,3-selenazoles attenuate microglial inflammatory responses through NF-kappaB inhibition. , 2008, European journal of pharmacology.

[4]  J. Malva,et al.  Neuropeptide Y inhibits interleukin‐1 beta‐induced microglia motility , 2012, Journal of neurochemistry.

[5]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[6]  J. Bethea,et al.  Targeting the host inflammatory response in traumatic spinal cord injury , 2002, Current opinion in neurology.

[7]  Jonathan Cohen.  The immunopathogenesis of sepsis , 2002, Nature.

[8]  M. K. Lee,et al.  Inhibition of inducible NO synthase, cyclooxygenase‐2 and interleukin‐1β by torilin is mediated by mitogen‐activated protein kinases in microglial BV2 cells , 2009, British journal of pharmacology.

[9]  A. Yoshimura,et al.  Post-Ischemic Inflammation in the Brain , 2012, Front. Immun..

[10]  J. Deleo,et al.  Morphine Enhances Microglial Migration through Modulation of P2X4 Receptor Signaling , 2009, The Journal of Neuroscience.

[11]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[12]  Stéphane Martin,et al.  Involvement of the Neurotensin Receptor-3 in the Neurotensin-Induced Migration of Human Microglia , 2003, The Journal of Neuroscience.

[13]  G. Bernardi,et al.  Post‐ischemic brain damage: pathophysiology and role of inflammatory mediators , 2009, The FEBS journal.

[14]  T. Möller,et al.  Microglia Biology in Health and Disease , 2006, Journal of Neuroimmune Pharmacology.

[15]  Tetsuro Ago,et al.  Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke , 2012, Journal of neurochemistry.

[16]  Mk Lee,et al.  Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells , 2009 .

[17]  W. J. Choi,et al.  A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats. , 2011, The American journal of pathology.

[18]  M. Schwab,et al.  Inflammation, degeneration and regeneration in the injured spinal cord: insights from DNA microarrays , 2003, Trends in Neurosciences.

[19]  W. Xu,et al.  Gua Lou Gui Zhi decoction exerts neuroprotective effects on post-stroke spasticity via the modulation of glutamate levels and AMPA receptor expression. , 2013, International journal of molecular medicine.

[20]  A. Nicolini,et al.  Effects of phosphatidylserine on p38 mitogen activated protein kinase, cyclic AMP responding element binding protein and nuclear factor‐κB activation in resting and activated microglial cells , 2003, Journal of neurochemistry.

[21]  Ruhui Lin,et al.  Gua Lou Gui Zhi decoction suppresses LPS-induced activation of the TLR4/NF-κB pathway in BV-2 murine microglial cells. , 2013, International journal of molecular medicine.

[22]  L. Hillered,et al.  Neuropathological endpoints in experimental stroke pharmacotherapy: The importance of both early and late evaluation , 2005, Acta Neurochirurgica.